Fighting Duchenne with collaborative data science

The Collaborative Trajectory Analysis Project (cTAP)

We are enabling leading clinical experts to solve critical problems in Duchenne drug development, now

Driven By Patient Data

1,300+ Patients

15+ Outcomes

10,000+ Clinic Visits

Our Platform

Agile Collaboration

Reap the benefits of collaboration, without the downsides

Unleash the power of patient data equitably, retain full control over the use of your data, align your funds with your priorities, simplify the ‘how’.

Leading Analytics

The right team, the best analytic solutions, today

Unrivaled academic access to skilled professionals, experienced in assembling the right teams connecting data and analytics, at scale, to solve practical challenges in rare disease drug development.

Empowered Drug Development

Conduct the right trial, the first time

Accelerate learning from natural history, explain phenotypic heterogeneity, access prognostic models and analytic tools to test trial designs iteratively and in real time.

Why We’re Here

Most pivotal trials in Duchenne have failed.

Have drug effects been hidden by unexpectedly high variability in patient outcomes? Or do the drugs not work?

In hindsight, trials have been clouded by high variability in rates of disease progression among patients.

Development Programs

Entered Clinical Trials

Pivotal Trials

Approvals

Shared Vision: Not bigger trials, smarter trials.


Gratitude

Clinical trials offer hope for Duchenne patients and families. Yet, clinical trials are taxing. All demand a major commitment of time and effort.

Almost 500 of the 1200+ patients enrolled in recent trials were assigned to placebo treatment.

Patients deserve clinical trials that reliably test the efficacy of a drug- not how well (or poorly) natural history is understood.

Our Team

The cTAP team is an unprecedented coalition of leaders bound together by common purpose and mutual respect, creativity in overcoming traditional barriers, and an unrelenting sense of urgency.

Clinical Experts in Duchenne

Eugenio Mercuri
Catholic University, Rome

Nathalie Goemans
UZ Leuven

Francesco Muntoni
University College London

Brenda Wong
Cincinnati Children's Hospital

Pharmaceutical Companies

Pfizer

BioMarin

Shire

Sarepta Therepeutics

PTC Therapeutics

Solid Biosciences

Catabasis Pharmaceuticals

Bristol-Myers Squibb

Patient Advocates

CureDuchenne
Founding organization

Parent Project Muscular Dystrophy

Analytic and Collaboration Leaders

James Signorovitch
Analysis Group Inc.

Susan J. Ward
The TAP Collaboration

Highlights

cTAP Overview

VIEW ARTICLE


cTAP Announces Two Research Publications Categorizing and Predicting Disease Progression in Duchenne Muscular Dystrophy

VIEW ARTICLE


Nonprofits, Pharmaceutical Companies and Noted Clinicians Join to Launch the Collaborative Trajectory Analysis Project (cTAP), Advancing Clinical Trial Design for Duchenne Muscular Dystrophy

Consortium Working Together to Bring Quality of Life Treatments to the Duchenne Community

VIEW ARTICLE


Prognostic model for 1 year change in 6MWD

Individualized prediction of changes in 6- minute walk distance for patients with Duchenne muscular dystrophy.
Nathalie Goemans, Marleen vanden Hauwe, James Signorovitch, Elyse Swallow, Jinlin Song, for the Collaborative Trajectory Analysis Project (cTAP). PLoS One, 2016, 0164684

VIEW ARTICLE


Clusters of patients with differing longitudinal trajectories

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
Eugenio Mercuri, James Edward Signorovitch, Elyse Swallow, Jinlin Song, and Susan J. Ward for the Trajectory Analysis Project Collaboration (cTAP) and the DMD Italian group. Neuromuscular Disorders 26 (2016) 576–583

VIEW ARTICLE